Supplementary data: Validity of HINT-8 in evaluating health-related quality of life among cervical cancer patients
Ah-Yeon Lee, Soo Hyun Lee, M Kim, Jing An et autres
0 citations
Figshare
Jung‐Yun Lee
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
612Publications signalées
8859Citations signalées
3Affiliations récentes
Les institutions déclarées
Les domaines associés
Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapyCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics
Les publications récentes
Supplementary data: Validity of HINT-8 in evaluating health-related quality of life among cervical cancer patients
Ah-Yeon Lee, Soo Hyun Lee, M Kim, Jing An et autres
0 citations
Figshare
Validity of HINT-8 in evaluating health-related quality of life among cervical cancer patients
Ah-Yeon Lee, Soo Hyun Lee, Min-Ju Kim, Jing An et autres
kr, jp, us (code pays fourni par la source)
0 citations
Journal of Comparative Effectiveness Research
Supplementary Data 1 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Vicky Makker, Jung‐Yun Lee, Do‐Youn Oh, Ana Oaknin et autres
0 citations
Table 1 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Vicky Makker, Jung‐Yun Lee, Do‐Youn Oh, Ana Oaknin et autres
0 citations
Supplementary Data S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Hyun‐Woong Cho, Jeong‐Yeol Park, Myong Cheol Lim, Byoung‐Gie Kim et autres
0 citations
Supplementary Table S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Hyun‐Woong Cho, Jeong‐Yeol Park, Myong Cheol Lim, Byoung‐Gie Kim et autres
0 citations
Data from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Vicky Makker, Jung‐Yun Lee, Do‐Youn Oh, Ana Oaknin et autres
1 citation
Supplementary Table S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Hyun‐Woong Cho, Jeong‐Yeol Park, Myong Cheol Lim, Byoung‐Gie Kim et autres
0 citations
Table 3 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Vicky Makker, Jung‐Yun Lee, Do‐Youn Oh, Ana Oaknin et autres
0 citations
Supplementary Table S4 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Hyun‐Woong Cho, Jeong‐Yeol Park, Myong Cheol Lim, Byoung‐Gie Kim et autres
0 citations
Supplementary Figure S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Hyun‐Woong Cho, Jeong‐Yeol Park, Myong Cheol Lim, Byoung‐Gie Kim et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.